STERIS plc (Ireland)

As of September 30, 2026, STERIS plc (Ireland) carries a market capitalization of 20.48B, placing it among publicly traded companies globally. Its enterprise value stands at 22.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

STERIS plc (Ireland)'s next confirmed earnings release is scheduled for February 10, 2027.

As of September 30, 2026, STERIS plc (Ireland) has 97.50M shares outstanding.

As of September 30, 2026, STERIS plc (Ireland) trades at a trailing price-to-earnings ratio of 24.84. The price-to-sales ratio is 3.33, and the price-to-book ratio stands at 2.82.

As of September 30, 2026, STERIS plc (Ireland) trades at an EV/EBITDA multiple of 13.22 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.81 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. STERIS plc (Ireland) trades at an EV/FCF ratio of 22.47, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 22.01B versus a market cap of 20.48B, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2026, STERIS plc (Ireland) maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.19, indicating elevated leverage, while an interest coverage ratio of 29.21 demonstrates strong ability to service its debt obligations.

Over the twelve months ended September 30, 2026, STERIS plc (Ireland) posted a return on equity (ROE) of 11.59, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.38 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.83, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.41, useful for judging operating efficiency across full business cycles. The company generates approximately 344,473.31 in revenue per employee across its workforce of 17,899.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.90 indicates how many times STERIS plc (Ireland) sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2026, STERIS plc (Ireland) recorded 294.10M in income tax expense. That works out to an effective tax rate of 26.17, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.12B, leaving 826.80M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on November 6, 2026, STERIS plc (Ireland)'s stock has declined approximately 2.98% over the past 52 weeks. The 50-day moving average sits at 220.57, while the 200-day moving average is 224.24.

Over the twelve months ended September 30, 2026, STERIS plc (Ireland) generated 6.17B in revenue and converted that into 826.80M in net income, yielding earnings per share of 8.46. EBITDA reached 1.66B, while operating income came in at 1.19B.

As of September 30, 2026, STERIS plc (Ireland) holds 531.10M in cash and equivalents against 2.05B in total debt, resulting in a net debt position of 1.36B. Total book value stands at 7.26B, with working capital of 1.27B providing operational flexibility.

STERIS plc (Ireland) produced 1.29B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -352.50M in capital expenditures, free cash flow totaled 937.20M - equivalent to 9.59 per share.

Over the twelve months ended September 30, 2026, STERIS plc (Ireland) posted a gross margin of 44.56, reflecting its pricing power and cost economics. The operating margin of 19.29 and net profit margin of 13.41 provide insight into operational efficiency.

Over the twelve months ended September 30, 2026, STERIS plc (Ireland) paid dividends of 2.58 per share. The dividend payout ratio of 30.28 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.55, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.80, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to STERIS plc (Ireland) shareholders.

STERIS plc (Ireland)'s most recent stock split took place on August 25, 1998 with a 1:2 split ratio.

As of September 30, 2026, STERIS plc (Ireland) has an Altman Z-Score of 6.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.